Literature DB >> 20175775

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Robyn J Barst1, Kamal K Mubarak, Roberto F Machado, Kenneth I Ataga, Raymond L Benza, Oswaldo Castro, Robert Naeije, Namita Sood, Paul S Swerdlow, Mariana Hildesheim, Mark T Gladwin.   

Abstract

Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40% mortality at 40 months. To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), respectively. Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16. The studies were terminated due to slow site initiation and patient enrolment (n = 26). Bosentan appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0.006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0.07) and between 6MWD and right atrial pressure (P = 0.08). In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0.06). Due to limited sample sizes, efficacy endpoints were not analysed. However, in both studies, non-significant increases in CO were observed with bosentan compared to placebo. Similarly, non-significant decreases in PVR were observed with bosentan. Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175775      PMCID: PMC2914575          DOI: 10.1111/j.1365-2141.2010.08097.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

Review 1.  Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research.

Authors:  K R Minter; M T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2001-12-01       Impact factor: 21.405

2.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.

Authors:  Vandana Sachdev; Roberto F Machado; Yukitaka Shizukuda; Yesoda N Rao; Stanislav Sidenko; Inez Ernst; Marilyn St Peter; Wynona A Coles; Douglas R Rosing; William C Blackwelder; Oswaldo Castro; Gregory J Kato; Mark T Gladwin
Journal:  J Am Coll Cardiol       Date:  2007-01-16       Impact factor: 24.094

3.  Modulation of Gardos channel activity by cytokines in sickle erythrocytes.

Authors:  Alicia Rivera; Petr Jarolim; Carlo Brugnara
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Authors:  Claudia R Morris; Sidney M Morris; Ward Hagar; Jane Van Warmerdam; Susan Claster; Diane Kepka-Lenhart; Lorenzo Machado; Frans A Kuypers; Elliott P Vichinsky
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

5.  Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.

Authors:  K J Sullivan; S R Goodwin; J Evangelist; R D Moore; P Mehta
Journal:  Crit Care Med       Date:  1999-11       Impact factor: 7.598

6.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Pulmonary hypertension in sickle cell disease.

Authors:  Kenneth I Ataga; Namita Sood; Guy De Gent; Eileen Kelly; Ashley G Henderson; Susan Jones; Dell Strayhorn; Alice Lail; Susan Lieff; Eugene P Orringer
Journal:  Am J Med       Date:  2004-11-01       Impact factor: 4.965

8.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Authors:  Oswaldo Castro; Mohammed Hoque; Bernice D Brown
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

Authors:  Robyn J Barst; Stuart Rich; Allison Widlitz; Evelyn M Horn; Vallerie McLaughlin; Joyce McFarlin
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  54 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

Review 2.  Balancing exercise risk and benefits: lessons learned from sickle cell trait and sickle cell anemia.

Authors:  Robert I Liem
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Soundos Saleh; Corina Becker; Reiner Frey; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 4.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

Review 5.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

Review 6.  Cardiovascular abnormalities in sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

7.  Is resistance futile?: Hemodynamics in sickle cell disease.

Authors:  Kerri Akaya Smith; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

8.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 9.  Endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Chao Liu; Junmin Chen; Yanqiu Gao; Bao Deng; Kunshen Liu
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 10.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.